Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
OBJECTIVE
To evaluate carotid intima-media thickness and thrombin-activatable fibrinolysis inhibitor levels in young women with polycystic ovary syndrome (PCOS) and age-matched healthy controls, and to investigate their relationship with each other and with clinical, metabolic, and hormonal parameters.


METHODS
Clinical study.


METHODS
University hospital.


METHODS
Fifty young women with PCOS (overweight or obese [n = 24] and nonobese [n = 26]) and 25 age-matched healthy controls.


METHODS
History and physical examination, peripheral venous blood sampling, carotid ultrasonography.


METHODS
Plasma thrombin-activatable fibrinolysis inhibitor, serum FSH, LH, DHEAS, total T, E(2), total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, insulin resistance defined by the homeostasis model assessment insulin resistance index, and carotid intima-media thickness.


RESULTS
Plasma thrombin-activatable fibrinolysis inhibitor levels in the overweight or obese PCOS group were significantly higher than those in the nonobese PCOS and control groups. Carotid intima-media thickness did not significantly differ between the groups. Obesity and insulin resistance were associated positively with plasma thrombin-activatable fibrinolysis inhibitor levels, but there was no association between carotid intima-media thickness and thrombin-activatable fibrinolysis inhibitor.


CONCLUSIONS
Young overweight or obese women with PCOS have increased plasma thrombin-activatable fibrinolysis inhibitor levels. Impaired fibrinolysis may be responsible for the increased risk of cardiovascular diseases in women with PCOS.
Adali
Ertan
E
Department of Obstetrics and Gynecology, Yuzuncu Yil University, Van, Turkey. ertanadali@gmail.com
Yildizhan
Recep
R
Kurdoglu
Mertihan
M
Bugdayci
Guler
G
Kolusari
Ali
A
Sahin
H Guler
HG
D000328:Adult; D025901:Carboxypeptidase B2 / Q000097:blood*; D002340:Carotid Artery Diseases / Q000000981:diagnostic imaging / Q000453:epidemiology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D016014:Linear Models; D007986:Luteinizing Hormone / Q000097:blood; D009765:Obesity / Q000097:blood* / Q000453:epidemiology*; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000453:epidemiology*; D012307:Risk Factors; D013739:Testosterone / Q000097:blood; D014280:Triglycerides / Q000097:blood; D017539:Tunica Intima / Q000000981:diagnostic imaging; D017540:Tunica Media / Q000000981:diagnostic imaging; D014463:Ultrasonography; D055815:Young Adult
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D013739:Testosterone; D004958:Estradiol; D019314:Dehydroepiandrosterone Sulfate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D025901:Carboxypeptidase B2